当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.

Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.

Abstract：

BACKGROUND:This study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability. PATIENTS AND METHODS:All patients that received NPLD for MBC at 5 institutions were identified. Clinicopathologic details, echocardiographic data, and toxicities were documented. Response to treatment, outcome, cardiotoxicity, and safety were assessed. RESULTS:63 patients (median age at NPLD therapy, 53.5 years) who had received NPLD were identified; 18 (29%) were anthracycline-naïve, and 42 (67%) were anthracycline-pretreated (median cumulative dose of epirubicin, 450 mg/m(2)). In 3 cases, prior treatment history was not available. NPLD was most frequently (16 [25%] of 63 patients) administered as first-line chemotherapy (median, third-line; range, 1-9), although it was given later in anthracycline-pretreated patients (median, fourth-line; range, 1-9). Overall, 14 (29%) of 49 evaluable patients achieved an objective response, which increased to 10 (71%) of 14 when NPLD was given first-line (anthracycline-naïve, 8 [100%] of 8; anthracycline-pretreated, 2 [50%] of 4; adjuvant treatment unknown, 2). Median progression-free survival was 7 months (first-line, 18 months, vs. ≥ second-line, 6 months; P = .0066), and median overall survival was 10 months (first-line, 18 months, vs. ≥ second-line, 10 months; P = .0971). Toxicities tended to be grade 1 or 2. Three patients had cardiotoxicity (left ventricular ejection fraction < 50% or a fall of ≥ 10% from baseline), which resolved during treatment. CONCLUSION:NPLD was used in both anthracycline-naïve patients and those with prior exposure. There is evidence of clinical activity in those with prior exposure to anthracyclines, with a low incidence of cardiotoxicity.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Palmieri C,Misra V,Januszewski A,Yosef H,Ashford R,Keary I,Davidson N

doi

10.1016/j.clbc.2013.10.011

subject

Has Abstract

pub_date

2014-04-01 00:00:00

pages

85-93

issue

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(13)00248-6

journal_volume

pub_type

杂志文章,多中心研究

在线工具

Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.